anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intervention was Preoperative bathing with antiseptic. Given warm water and a tablet soap containing chloroxylenol antiseptic. Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
One of the most challenging morbidities after breast cancer treatment is lymphedema. Approximately 20% of women treated for breast cancer with axillary lymph node dissection will be diagnosed with lymphedema. Pre- and post-operatively, women are informed about changes suggestive of lymphedema and guided about seeking further assessment. The investigators presume that if symptoms occur, patients will seek assessment. However, it is unknown whether this is true or if those prospectively monitored present earlier for treatment, or whether other factors specifically drive patients to seek further assessment. Understanding the early experience and presentation of secondary lymphedema will improve patient education and detection programs.
PURPOSE:A bathing agent containing a liquid oil component and water, obtained by blending specific amounts of specified lipophilic nonionic surface active agent and hydrophilic nonionic surface active agent in a specific ratio. CONSTITUTION:A lipophilic nonionic surface active agent (e.g., sorbitan monooleate, sorbitan sesquioleate, etc.) which is liquid at normal temperature (30 deg.C) and has <=8 HLB is blended with a hydrophilic nonionic surface active agent [e.g., polyoxyethylene sorbitan monooleate (20E.O.) etc.] which is liquid at normal temperature and has >=10 HLB in a weight ratio of 1:4-3:1 in such a way that the total amount of them is 6-25wt% based on total amounts of a bathing agent, and the blend is mixed with 50-92wt% oil component (e.g., hydrocarbon such as liquid paraffin, ester such as isopropyl myristate, etc., vegetable oil such as jujube oil, etc.) which is liquid at normal temperature and 0.1-10wt% water to give a bathing agent which has beautiful visual effect and is good for health of the skin and body. The bathing agent may be blended with a germicide, refreshing agent, etc. used for cosmetic.
Intravaginal cream containing metronidazole (500 mg), nystatin ( 100.000 UI) and dexamethasone (0,32 mg) once a day. Period: 10 days.
Vanillic acid (VA) - a naturally occurring phenolic compound in plants - is not only used as a flavoring agent but also a prominent metabolite post tea consumption. VA and its associated compounds are believed to play a significant role in preventing diseases, underscoring the need for a systematic investigation. Herein, we report a 4-step synthesis employing the classical organic reactions, such as Willamson's alkylation, Fischer-Spier reaction, and Steglich esterification, complemented with a protection-deprotection strategy to prepare 46 VA derivatives across the five series (1a-1i, 2a-2i, 3, 3a-3i, 4a-4i, 5a-5i) in high yields. The synthesized compounds were investigated for their antifungal, anti-inflammatory, and toxic effects. Notably, compound 1a demonstrated remarkable ROS inhibition with an IC50 value of 5.1 ± 0.7 µg/mL, which is more than twice as effective as the standard ibuprofen drug. A subset of the synthesized derivatives (2b, 2c, 2e, 3b-3d, 4a-4c, 5a, and 5e) manifested their antifungal effect against drug-resistant Candida strains. Compound 5g, in particular, revealed synergism with the established antifungal drugs amphotericin B (AMB) and fluconazole (FLZ), doubling FLZ's potency against azole resistant Candida albican ATCC 36082. Furthermore, 5g improved the potency of these antifungals against FLZ-sensitive strains, including C. glabrata ATCC 2001 and C. parapsilosis ATCC 22019, as well as various multidrug-resistant (MDR) Candida strains, namely C. albicans ATCC 14053, C. albicans CL1, and C. krusei SH2L OM341600. Additionally, pharmacodynamics of compound 5g was examined using time-kill assay, and a benign safety profile was observed with no hemolytic activity in whole blood, and no cytotoxicity towards the normal BJ human cell line. The synergistic potential of 5g was further investigated through both experimental methods and docking simulations.These findings highlight the therapeutic potential of VA derivatives, particularly in addressing inflammation and circumventing FLZ resistance in Candida albicans.
For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenlum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum or any bone structure.Following the bleeding control, the wound site was left to secondary healing. No sutures were necessary after procedure.
The study is an interventional triple-blind, placebo-controlled, parallel group design with 2 arms (placebo, butyrate). Healthy male participants adhere to a low-fiber diet for the duration of the study (11 days). At the baseline study visit, measurements are taken in the lab, including biological samples and psychophysiological measurements. Participants then consume placebo or butyrate for 1 week and revisit the lab on day 11 for a second measurement of the outcomes of interest. Specifically, we investigate the effect of colonic butyrate administration on affective processing, including stress sensitivity and fear-related processes (e.g. extinction learning). Volunteers also respond to questionnaires in relation to mood and GI symptoms, and provide biological samples (saliva, blood, and faecal samples) for analysis of cortisol levels, circulating short chain fatty acids and serum BDNF, and faecal SCFA, respectively.
Critical care uses syndromic definitions to describe patient groups for clinical practice and research. There is growing recognition that a "precision medicine" approach is required and that integrated biologic and physiologic data identify reproducible subpopulations that may respond differently to treatment. This article reviews the current state of the field and considers how to successfully transition to a precision medicine approach. To impact clinical care, identification of subpopulations must do more than differentiate prognosis. It must differentiate response to treatment, ideally by defining subgroups with distinct functional or pathobiological mechanisms (endotypes). There are now multiple examples of reproducible subpopulations of sepsis, acute respiratory distress syndrome, and acute kidney or brain injury described using clinical, physiological, and/or biological data. Many of these subpopulations have demonstrated the potential to define differential treatment response, largely in retrospective studies, and that the same treatment-responsive subpopulations may cross multiple clinical syndromes (treatable traits). To bring about a change in clinical practice, a precision medicine approach must be evaluated in prospective clinical studies requiring novel adaptive trial designs. Several such studies are underway, but there are multiple challenges to be tackled. Such subpopulations must be readily identifiable and be applicable to all critically ill populations around the world. Subdividing clinical syndromes into subpopulations will require large patient numbers. Global collaboration of investigators, clinicians, industry, and patients over many years will therefore be required to transition to a precision medicine approach and ultimately realize treatment advances seen in other medical fields.
Patients will be administered 3 times (X) 30 International unis per kilogram(IU/Kg body weight per week of eopetin beta subcurtaneously using the device RecoPen. The dosage could be increased every 4 weeks by 3 X20 IU/Kg.
The present invention provides a blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea which comprises the following raw materials by weight: 10 to 50 parts of Chinese wolfberry root-bark, 10 to 20 parts of parasite scurrula, 10 to 20 parts of slenderstyle acanthopanax rootbark, 10 to 20 parts of white mulberry root-bark, 10 to 20 parts of common macrocarpium fruit, 10 to 20 parts of tuckahoe, 10 to 20 parts of Salvia miltiorrhiza, 10 to 20 parts of szechwan lovage rhizome, 10 to 20 parts of simpleleaf shrub chastetree fruit, 10 to 20 parts of radix polygoni multiflori preparata, 10 to 20 parts of common curculigo rhizome, 10 to 20 parts of mulberry fruit, 10 to 20 parts of glossy privet fruit, 10 to 20 parts of white peony root, 10 to 20 parts of giant knotweed rhizome and 10 to 20 parts of barbed skullcap herb. The Chinese wolfberry root-bark decoction has functions of slaking wasting-thirst and frequent taking of water day and night, and inducing urination. Modern pharmacological studies show that: the Chinese wolfberry root-bark contains guanidine derivatives which have hypoglycemic effect. The Chinese wolfberry root-bark health care tea also has blood lipid reducing and blood pressure reducing effects which are concerned with the central nervous system and maybe are induced by direct vasodilatation through blocking the sympathetic nerve endings. The Chinese wolfberry root-bark health care in the present invention has overflowing fragrance and little bitter, sweet and mellow taste. The addition of Chinese herbs with function of activating blood circulation and dissipating blood stasis, with light taste, and without destruction of the sweet taste of Chinese wolfberry root-bark does not affect the taste, is readily accepted by people, and can provide good blood lipid and blood glucose reducing efficacy.
Leuconostoc lactis DMLL10 is a microorganism specific to kimchi fermentation. In this study, we sought to evaluate the toxicity of this strain, which was newly isolated from kimchi, to determine its safety as a food ingredient. Bacterial reverse mutation assay, chromosomal aberration assay, and mammalian cell in vitro micronucleus assay were performed to assess the genetic toxicity of Leu. lactis DMLL10. The strain did not induce mutagenicity in Salmonella typhimurium TA98, TA100, TA1535, TA1537, or Escherichia coli WP2uvrA, with or without metabolic activation of S9 mixture. The oral administration of Leu. lactis DMLL10 also did not significantly increase the number of micronucleated polychromatic erythrocytes, or the mean ratio of polychromatic to total erythrocytes. Additionally, Leu. lactis DMLL10 did not cause a significant chromosomal aberration in CHU/IL cells in the presence or absence of S9 activation. Therefore, Leu. lactis DMLL10 can be suggested as a functional food ingredient with reliability and safety.
A polynucleotide comprising a cysteine-cysteine chemokine receptor 3(CCR3) and an IL-5RA genetic polymorphism is provided to be valuable as a diagnosing biomarker regarding eosinophilia, which is an intermediate phenotype and useful for designing a novel therapeutic method of diseases related to the eosinophilia. A biomarker for diagnosing eosinophilia in asthmatics comprises at least one polynucleotide selected from polynucleotides consisting of 20-30 consecutive DNA sequences of SEQ ID : NO. 1, where a 30th base is A, at least one polynucleotide selected from polynucleotides consisting of 20-30 consecutive DNA sequences of SEQ ID : NO. 2, where a 30th base is G, at least one polynucleotide selected from polynucleotides consisting of 20-30 consecutive DNA sequences of SEQ ID : NO. 3, where a 30th base is T, at least one polynucleotide selected from polynucleotides consisting of 20-30 consecutive DNA sequences of SEQ ID : NO. 4, where a 30th base is A, or at least one polynucleotide selected from polynucleotides consisting of 20-30 consecutive DNA sequences of SEQ ID : NO. 1, where a 30th and a 30th base are TG. A kit for diagnosing eosinophilia in asthmatics comprises at least one of the biomarker and a direction letter describing a method for using the biomarker.
Subjects that meet study inclusion criteria will be recruited from the Adult and Pediatric Gastroenterology clinics at Walter Reed National Military Medical Center through routine clinic visits, will meet with an investigator, and complete informed consent/assent. The participants will then complete a validated clinical symptom reporting tool - the Eosinophilic Esophagitis symptom activity index (EEsAI) for age 18 and above, or the Pediatric Quality of Life Inventory (PedsQL) for age 6-17yrs - and have their initial Esophagogastroduodenoscopy (EGD) images evaluated via a validated Endoscopic Reference Score (EREFS). Esophageal biopsies taken at the patient's initial EGD will be assessed by 2 designated blinded pathologists to record the number of eosinophils per high power field (HPF), as well as perform tissue immunohistochemical staining for eotaxin-3. Participants will be block randomized to treatment or control groups and complete 8 weeks of therapy, with a phone follow up at 4 weeks for medication compliance. At the completion of 8 weeks of therapy, the participants will have repeat EGD to assess for mucosal healing, which is the standard of care in the treatment of EoE. At this EGD, the images will be assigned an EREFS and the biopsies will be evaluated for eosinophils per high powered field and eotaxin-3 staining. The patient will also complete an EEsAI or PedsQL. This procedure will end the 8 week study period.
PURPOSE:To obtain a readily handleable dental cement, excellent in biocompatibility and having a high strength by combining calcium oxide with magnesium oxide and silicon oxide or further adding calcium fluoride thereto. CONSTITUTION:The dental cement material comprises calcium oxide (10-87.5wt.%), magnesium oxide (2.5-80.0wt.%) and silicon oxide (10-87.5wt.%). Furthermore, calcium fluoride (preferably about 30wt.%) can be contained to regulate the hardening time and operation time and the vitrification is easily carried out. A polycarboxylic acid-based hardening agent is added and the resultant material is preferably kneaded for use. Since this cement material is good in biocompatibility, irritation is hardly caused even in filling this material in a deep cavity with a thin dentine. Sufficient adhesion is manifested by its use with the hardening agent. Since this material has a high strength and a sufficient strength is especially obtained in vitrification thereof, it can be used as a cementing agent.
Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
NEW MATERIAL:The glutamic acid receptor-inhibiting substance having the following characteristics. Molecular weight, 500+ or -200; solubility, hardly soluble in ethyl acetate and soluble in water; stability, resistant to the heating at 80 deg.C for 20min in the form of aqueous solution, and resistant to the heating at 80 deg.C for 20 min in a 0.4M perchloric acid; exhibits neutral charge by electrophoresis using 0.01M phosphoric acid buffer solution (pH 7); emits fluorescence by fluorescamine; Rf value, 0.20 by silica gel thin-layer chromatography. USE:Insecticide. Especially effective to rice stem borer, green caterpillar, aphids, etc. PREPARATION:Nephila clavate (silk spider) is collected, disintegrated with an atomizer, etc., and extracted with water, an aqueous solution of electrolyte, or a mixture of water and an organic solvent miscible homogeneously with water. The extract is separated into the liquid and residue by centrifugal separator, etc., and preferably the high-molecular protein is removed. The extract is concentrated under reduced pressure, and purified e.g. by gelfiltration, etc. to obtain the objective glutamic acid receptorinhibiting substance.
PURPOSE:To obtain a hair dye for hair capable of permeating a mordant capable of forming a complex with a vegetable pigment dye and forming a color and the above-mentioned vegetable pigment dye into hair tissues, polymerizing fine particles of metallic low molecular substances with the aforementioned vegetable pigment dye and coloring the hair by ionizing the mordant, providing the first agent and using the above-mentioned vegetable pigment dye permeating into the hair tissues as the second agent. CONSTITUTION:A hair dye composed of the first agent consisting essentially of a mordant composed of a metal of iron, chromium, manganese, etc., without damaging human bodies, an alcohol and purified water and the second agent consisting essentially of a vegetable pigment dye such as hematin, henna tannin or catechin, an alcohol and purified water. The first agent is permeated into hair tissues and ionized to provide a mordant. The resultant mordant as fine particles of metallic low molecular substances is made to remain in the hair tissues. The second agent is then permeated into the hair tissues to combine and polymerize the fine particles of the metallic low-molecular substances remaining in the above-mentioned tissues with the aforementioned dye in the hair tissues. Thereby, the hair tissues are incorporated, colored and fixed during the polymerization.
Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
BACKGROUND: The risk of metachronous advanced neoplasia after diagnosing serrated polyps in patients with IBD is poorly understood.
METHODS: A retrospective multicenter cohort study was conducted between 2010 and 2019 at three tertiary centers in Montreal, Canada. From pathology databases, we identified 1587 consecutive patients with serrated polyps (sessile serrated lesion, traditional serrated adenoma, or serrated epithelial change). We included patients aged 45-74 and excluded patients with polyposis, colorectal cancer, or no follow-up. The primary outcome was the risk of metachronous advanced neoplasia (advanced adenoma, advanced serrated lesion, or colorectal cancer) after index serrated polyp, comparing patients with and without IBD.
RESULTS: 477 patients with serrated polyps were eligible (mean age 61 years): 37 with IBD, totaling 45 serrated polyps and 440 without IBD, totaling 586 serrated polyps. The median follow-up was 3.4 years. There was no difference in metachronous advanced neoplasia (HR 0.77, 95% CI 0.32-1.84), metachronous advanced adenoma (HR 0.54, 95% CI 0.11-2.67), and metachronous advanced serrated lesion (HR 0.76, 95% CI 0.26-2.18) risk. When comparing serrated polyps in mucosa involved or uninvolved with IBD, both groups had similar intervals from IBD to serrated polyp diagnosis (p > 0.05), maximal therapies (p > 0.05), mucosal inflammation, inflammatory markers, and fecal calprotectin (p > 0.05).
CONCLUSION: The risk of metachronous advanced neoplasia after serrated polyp detection was similar in patients with and without IBD. Serrated polyps in IBD occurred independently of inflammation. This helps inform surveillance intervals for patients with IBD diagnosed with serrated polyps.
Atrial fibrillation (AF) emerges as a critical complication following acute myocardial infarction (AMI) and is associated with a significant increased risk of heart failure, stroke and mortality. Ataxia telangiectasia mutated (ATM), a key player in DNA damage repair (DDR), has been implicated in multiple cardiovascular conditions, however, its involvement in the development of AF following AMI remains unexplored. This study seeks to clarify the contribution of the ATM/p53 pathway in the onset of AF post-AMI and to investigate the underlying mechanisms. The rat model of AMI was established by ligating left anterior descending coronary artery in the presence or absence of Ku55933 (an ATM kinase inhibitor, 5 mg/kg/d) treatment. Rats receiving Ku55933 were further divided into the early administration group (administered on days 1, 2, 4, and 7 post-AMI) and the late administration group (administered on days 8, 9, 11 and 14 post-AMI). RNA-sequencing was performed 14 days post-operation. In vitro, H2O2-challenged HL-1 atrial muscle cells were utilized to evaluate the potential effects of different ATM inhibition schemes, including earlier, middle, and late periods of intervention. Fourteen days post-AMI injury, the animals exhibited significantly increased AF inducibility, exacerbated atrial electrical/structural remodeling, reduced ventricular function and exacerbated atrial DNA damage, as evidenced by enhanced ATM/p53 signaling as well as γH2AX level. These effects were partially consistent with the enrichment results of bioinformatics analysis. Notably, the deleterious effects were ameliorated by early, but not late, administration of Ku55933. Mechanistically, inhibition of ATM signaling successfully suppressed atrial NLRP3 inflammasome-mediated pyroptotic pathway. Additionally, the results were validated in the in vitro experiments demonstrating that early inhibition of Ku55933 not only attenuated cellular ATM/p53 signaling, but also mitigated inflammatory response by reducing NLRP3 activation. Collectively, hyperactivation of ATM/p53 contributed to the pathogenesis of AF following AMI. Early intervention with ATM inhibitors substantially mitigated AF susceptibility and atrial electrical/structural remodeling, highlighting a novel therapeutic avenue against cardiac arrhythmia following AMI.
PURPOSE: A composition containing medicinal herb extract is provided, which inhibits the activity of pancreatic cholesterol esterase specifically, and decreases the internal absorption of cholesterol. CONSTITUTION: A process for the production of the composition comprises: selecting more than one of medicinal herb from Cinnamomi cortex, Eucommia bark, Magnolia bark, Phellodendron bark, Evidia fruit, Nutmeg, Ephedra herb, Menthae herba, Safflower, Equiseti herba, Biotae orientalis Forium, Kalopanacis cortex, Typhae pollen, Alpinia Katsumadai semen, Siegesbeckiae herba, Psoraleae semen, Alphiniae officinari Rhisoma, and Trichosanthis semen; chopping the medicinal herbs and extracting with solvents such as distilled water, ethanol, methanol, butanol, ethyl acetate or acetone. The composition can be prepared for tablets, capsules and injections. The dosage forms a tablet and a capsule contain diluents(e.g. lactose, dextrose, sucrose, mannitol, sorbitol) and lubricants(e.g. silica, talc, stearic acid and its salt form, and/or polyethylene glycol). The threshold dose range of the extract is 0.01-5g/kg a day.